FIBRONEER-SARD: Treating ILD associated with Autoimmune Disease

Trial Objectives

Continuous scarring (fibrosis) can gradually impair lung function, leading to breathing difficulties. Some autoimmune conditions, which lead to inflammation and damage throughout the body, can cause lung fibrosis. This combination of conditions is known as systemic autoimmune rheumatic diseases associated interstitial lung diseases, or SARD-ILD. Researchers want to determine if a new medication can help people with lung fibrosis related to autoimmune conditions, whose symptoms haven’t been improved by the immunosuppressant treatment.

Volunteers will  randomly receive either the new study medication called nerandomilast or a placebo (a medication with no active ingredient). During clinic visits, volunteers will receive lung function tests, get CT scans of the chest, and complete questionnaires about their health and symptoms.